Alkermes plc (NASDAQ: ALKS) today reported financial results for the first quarter of 2014.
“During the quarter, we continued to generate positive cash flow, reflecting the strength of our commercial business and enabling us to invest in our advancing late-stage pipeline and prepare for the launch of aripiprazole lauroxil,” commented James Frates, Chief Financial Officer of Alkermes. “With more than $700 million in cash and investments and a cash-generating commercial portfolio, Alkermes is well-positioned to build our business. The business continues to perform as we planned, and today we are reiterating the financial expectations for 2014 that we provided in February.”
Help employers find you! Check out all the jobs and post your resume.
